Barwon Investment Partners (Barwon) is pleased to announce that the Barwon Healthcare Property Fund (Fund) has received a “Recommended” rating from Zenith Investment Partners.
The Fund provides investors with exposure to investments in Australian healthcare property assets which carry traditional commercial leases and strong tenant covenants. The Fund secures investments with good design and functional attributes, ensuring the asset is fit for healthcare purposes for the long term. The Fund aims to provide investors with an income of circa 6% per annum with the potential for some capital growth.
In its research report, Zenith noted the “Recommended” rating was based upon the expanding team of 17 members and Barwon’s growth in assets under management. Zenith views the Fund as a differentiated, specialist, single sector offering. They view the portfolio as being sufficiently diversified by geography and assets.
Tom Patrick, Head of Healthcare Property says, “The Fund provides investors with access to a portfolio of Australian healthcare properties including hospitals, private specialist facilities, day surgeries, diagnostic and laboratory facilities.
“Our team expansion will ensure we are equipped to source new investments and manage the existing investments across the portfolio for our investors. Pleasingly, the Fund has returned 10.5% over the 12 months to December 2020, showcasing the resiliency of healthcare real estate during turbulent markets.”
Barwon has been investing in the healthcare property sector since 2014 over which time it has invested over $1 billion across more than 50 healthcare assets.
For further information please contact:
Co-Head of Property, Partner 0411 150 242
Head of Healthcare Property
0429 594 563
About Barwon Investment Partners
Barwon Investment Partners is a Sydney-based fund manager with a 14-year track record of generating strong investment returns for institutional and wholesale clients.
With expertise in healthcare real estate, property finance and global investments, Barwon manages $1.9 billion on behalf of its clients.
The Zenith Investment Partners (ABN 27 103 132 672, AFS Licence 226872) (“Zenith”) rating (assigned December 2020) referred to in this document is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at http://www.zenithpartners.com.au/RegulatoryGuidelines